Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Jun 5. pii: mdz171. doi: 10.1093/annonc/mdz171. [Epub ahead of print] No abstract available.

PMID:
31168601
2.

Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma.

Miller TA, Robinson KR, Li H, Seiwert TY, Haraf DJ, Lan L, Giger ML, Ginat DT.

Quant Imaging Med Surg. 2019 Mar;9(3):399-408. doi: 10.21037/qims.2019.03.08.

3.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522.

PMID:
30481287
4.

Management of Early Head and Neck Cancer in Elderly Patients.

Jelinek MJ, Howard AS, Haraf DJ, Vokes EE.

J Oncol Pract. 2018 Sep;14(9):541-546. doi: 10.1200/JOP.18.00078.

PMID:
30285530
5.

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ.

Oral Oncol. 2018 May;80:16-22. doi: 10.1016/j.oraloncology.2018.03.008. Epub 2018 Mar 16.

PMID:
29706184
6.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.

PMID:
27511844
7.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.

PMID:
26884588
8.

Reply to s. Chakraborty et al.

Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE.

J Clin Oncol. 2015 Mar 10;33(8):968. doi: 10.1200/JCO.2014.59.6189. Epub 2015 Feb 9. No abstract available.

PMID:
25667282
9.

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.

Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EE, Seiwert TY, Haraf DJ, Vokes EE.

Ann Oncol. 2015 Jan;26(1):198-205. doi: 10.1093/annonc/mdu511. Epub 2014 Oct 30.

PMID:
25361984
10.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

11.

Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.

Maggiore RJ, Curran EK, Witt ME, Haraf DJ, Vokes EE, Cohen EE.

J Geriatr Oncol. 2013 Oct;4(4):327-33. doi: 10.1016/j.jgo.2013.05.003. Epub 2013 Jun 10.

12.

Race and competing mortality in advanced head and neck cancer.

Zakeri K, MacEwan I, Vazirnia A, Cohen EE, Spiotto MT, Haraf DJ, Vokes EE, Weichselbaum RR, Mell LK.

Oral Oncol. 2014 Jan;50(1):40-4. doi: 10.1016/j.oraloncology.2013.09.012. Epub 2013 Oct 14.

13.

Lymph node density--prognostic value in head and neck cancer.

Rudra S, Spiotto MT, Witt ME, Blair EA, Stenson K, Haraf DJ.

Head Neck. 2014 Feb;36(2):266-72. doi: 10.1002/hed.23299. Epub 2013 Jun 14.

PMID:
23765406
14.

Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.

Golden DW, Rudra S, Witt ME, Nwizu T, Cohen EE, Blair E, Stenson KM, Vokes EE, Haraf DJ.

Oral Oncol. 2013 Mar;49(3):277-82. doi: 10.1016/j.oraloncology.2012.10.003. Epub 2012 Oct 25.

PMID:
23102863
15.

Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.

Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK.

Oral Oncol. 2012 Oct;48(10):1025-1030. doi: 10.1016/j.oraloncology.2012.04.004. Epub 2012 May 22.

PMID:
22621836
16.

Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.

Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK.

J Thorac Oncol. 2012 Feb;7(2):376-81. doi: 10.1097/JTO.0b013e31824166a5.

17.

Chemoradiation for patients with large-volume laryngeal cancers.

Stenson KM, Maccracken E, Kunnavakkam R, W Cohen EE, Portugal LD, Villaflor V, Seiwert T, Blair E, Haraf DJ, Salama JK, Vokes EE.

Head Neck. 2012 Aug;34(8):1162-7. doi: 10.1002/hed.21888. Epub 2011 Nov 3.

PMID:
22052816
18.

Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR.

Cancer. 2012 Jun 1;118(11):2962-70. doi: 10.1002/cncr.26611. Epub 2011 Oct 21.

19.

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.

Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA.

Head Neck Oncol. 2011 Jul 26;3:31. doi: 10.1186/1758-3284-3-31.

20.

Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.

Shumway D, Corbin K, Salgia R, Hoffman P, Villaflor V, Malik RM, Haraf DJ, Vigneswaren WT, Shaikh AY, Connell PP, Ferguson MK, Salama JK.

Lung Cancer. 2011 Dec;74(3):446-50. doi: 10.1016/j.lungcan.2011.05.003. Epub 2011 Jun 14.

PMID:
21676484
21.

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.

Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK.

Cancer. 2011 Oct 15;117(20):4671-8. doi: 10.1002/cncr.26084. Epub 2011 Jun 13.

22.

Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.

Pederson AW, Salama JK, Witt ME, Stenson KM, Blair EA, Vokes EE, Haraf DJ.

Am J Clin Oncol. 2011 Aug;34(4):356-61. doi: 10.1097/COC.0b013e3181e8420b.

PMID:
21633289
23.

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.

Salama JK, Haraf DJ, Stenson KM, Blair EA, Witt ME, Williams R, Kunnavakkam R, Cohen EE, Seiwert T, Vokes EE.

Ann Oncol. 2011 Oct;22(10):2304-9. doi: 10.1093/annonc/mdq736. Epub 2011 Feb 17.

PMID:
21330337
24.

Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.

Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK.

Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1226-34. doi: 10.1001/archoto.2010.218.

PMID:
21173372
25.

Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.

Choe KS, Salama JK, Stenson KM, Blair EA, Witt ME, Cohen EE, Haraf DJ, Vokes EE.

Radiother Oncol. 2010 Nov;97(2):318-21. doi: 10.1016/j.radonc.2010.09.003. Epub 2010 Oct 9.

PMID:
20934766
26.

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE.

J Clin Oncol. 2010 Jul 10;28(20):3336-43. doi: 10.1200/JCO.2009.27.0397. Epub 2010 May 24.

27.

Chemoreirradiation for recurrent salivary gland malignancies.

Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE, Salama JK.

Radiother Oncol. 2010 Jun;95(3):308-11. doi: 10.1016/j.radonc.2010.03.006. Epub 2010 Apr 10.

PMID:
20385414
28.

Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue.

Pederson AW, Haraf DJ, Witt ME, Stenson KM, Vokes EE, Blair EA, Salama JK.

Head Neck. 2010 Nov;32(11):1519-27. doi: 10.1002/hed.21360.

PMID:
20187015
29.

Predictors of competing mortality in advanced head and neck cancer.

Mell LK, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, Bhate AD, Witt ME, Haraf DJ, Mittal BB, Vokes EE, Weichselbaum RR.

J Clin Oncol. 2010 Jan 1;28(1):15-20. doi: 10.1200/JCO.2008.20.9288. Epub 2009 Nov 23.

PMID:
19933920
30.

Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.

Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, Stenson KM.

Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1133-6. doi: 10.1001/archoto.2009.154.

PMID:
19917927
31.

Chemoradiation for patients with advanced oral cavity cancer.

Stenson KM, Kunnavakkam R, Cohen EE, Portugal LD, Blair E, Haraf DJ, Salama J, Vokes EE.

Laryngoscope. 2010 Jan;120(1):93-9. doi: 10.1002/lary.20716.

PMID:
19856305
32.

Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.

Cohen EE, Baru J, Huo D, Haraf DJ, Crowley M, Witt ME, Blair EA, Weichselbaum RR, Rosen F, Vokes EE, Stenson K.

Head Neck. 2009 Aug;31(8):1013-21. doi: 10.1002/hed.21062.

PMID:
19340870
33.

Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.

Salama JK, Stenson KM, List MA, Mell LK, Maccracken E, Cohen EE, Blair E, Vokes EE, Haraf DJ.

Arch Otolaryngol Head Neck Surg. 2008 Oct;134(10):1060-5. doi: 10.1001/archotol.134.10.1060.

PMID:
18936351
34.

Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.

Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE.

J Thorac Oncol. 2008 Sep;3(9):1003-11. doi: 10.1097/JTO.0b013e31818396a4.

35.

An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease.

Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR.

Clin Cancer Res. 2008 Aug 15;14(16):5255-9. doi: 10.1158/1078-0432.CCR-08-0358.

36.

Free-flap reconstruction in the doubly irradiated patient population.

Cohn AB, Lang PO, Agarwal JP, Peng SL, Alizadeh K, Stenson KM, Haraf DJ, Cohen EE, Vokes EE, Gottlieb LJ.

Plast Reconstr Surg. 2008 Jul;122(1):125-32. doi: 10.1097/PRS.0b013e3181773d39.

PMID:
18594395
37.

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE.

Ann Oncol. 2008 Oct;19(10):1787-94. doi: 10.1093/annonc/mdn364. Epub 2008 Jun 6.

PMID:
18539617
38.

Radiation-induced leiomyosarcoma: does antimetabolite chemotherapy contribute? A report of three cases.

Brockstein B, Mundt A, Haraf DJ, Ferguson M, Montag A.

Sarcoma. 2003;7(3-4):167-72. doi: 10.1080/13577140310001650330.

39.

Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.

Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE.

Ann Oncol. 2008 Sep;19(9):1650-4. doi: 10.1093/annonc/mdn173. Epub 2008 May 7.

PMID:
18467314
40.

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, Kocherginsky M, Weichselbaum RR, Chen HX, Vokes EE.

J Clin Oncol. 2008 Apr 1;26(10):1732-41. doi: 10.1200/JCO.2007.13.1706.

PMID:
18375903
41.

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.

J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566.

42.

Aspiration in chemoradiated patients with head and neck cancer.

Langerman A, Maccracken E, Kasza K, Haraf DJ, Vokes EE, Stenson KM.

Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1289-95.

PMID:
18086974
43.

A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.

Seiwert TY, Cohen EE, Haraf DJ, Stenson K, Blair EA, Mauer A, Dekker A, Vokes EE.

Cancer Invest. 2007 Sep;25(6):435-44.

PMID:
17882655
44.

Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers.

Shaikh AY, Haraf DJ, Salama JK, Salgia R, Hoffman PC, Ferguson MK, Connell PP.

Am J Clin Oncol. 2007 Jun;30(3):258-63.

PMID:
17551302
45.

Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

Cohen EE, Rosine D, Haraf DJ, Loh E, Shen L, Lusinchi A, Vokes EE, Bourhis J.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):678-84.

PMID:
17293229
46.

A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.

Seiwert TY, Connell PP, Mauer AM, Hoffman PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ, Vokes EE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):515-22.

47.

Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer.

Lazarus C, Logemann JA, Pauloski BR, Rademaker AW, Helenowski IB, Vonesh EF, Maccracken E, Mittal BB, Vokes EE, Haraf DJ.

Head Neck. 2007 Jul;29(7):632-7.

PMID:
17230558
48.

High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.

Cohen EE, Haraf DJ, List MA, Kocherginsky M, Mittal BB, Rosen F, Brockstein B, Williams R, Witt ME, Stenson KM, Kies MS, Vokes EE.

J Clin Oncol. 2006 Jul 20;24(21):3438-44.

49.

Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.

Milano MT, Vokes EE, Kao J, Jackson W, List MA, Stenson KM, Witt ME, Dekker A, MacCracken E, Garofalo MC, Chmura SJ, Weichselbaum RR, Haraf DJ.

Int J Oncol. 2006 May;28(5):1141-51.

PMID:
16596230
50.

Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.

Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE, Lingen MW.

Int J Oncol. 2006 May;28(5):1113-9.

PMID:
16596227

Supplemental Content

Loading ...
Support Center